Hydroxysteroid (17-beta) dehydrogenase (HSD17B) are the enzymes responsible for the reversible interconversion of 17-hydroxy and 17-keto steroids. The human and mouse type 8 17b-HSD (HSD17B8) selectively catalyze the conversion of estradiol (E2) to estrone (E1). We previously described that HSD17B8 is transcriptionally regulated by C/EBPb, and that C/EBPb is bound to CCAAT boxes located at K5 and K46 of the transcription start site in basal conditions in HepG2 cells. Furthermore, ectopic expression of C/EBPb transactivated the HSD17B8 promoter activity. Here, we show that HSD17B8 expression is up-regulated in response to E2 in the estrogen receptor a (ERa) positive MCF-7 cells. Results showed that this induction is mediated by ERa because i) E2 did not induce HSD17B8 expression in ERa negative HepG2 cells, ii) ectopic expression of ERa restored E2-induced HSD17B8 expression, and iii) this induction was blocked by the anti-ER ICI 182 780. Additional experiments showed that no estrogen response element was necessary for this regulation. However, the CCAAT boxes located at the HSD17B8 proximal promoter were required for E2-induced transcription. Furthermore, co-immunoprecipitation studies revealed tethering of ERato C/EBPb in response to E2 in cells expressing ERa. Additionally, chromatin immunoprecipitation assays demonstrated that, in response to E2, ERa is recruited to the CCAAT boxes in which C/EBPb is already bound. Taken together, our results reveal that ERa is involved in the transcriptional regulation of HSD17B8 gene in response to E2 through its interaction with C/EBPb.
Introduction
The hydroxysteroid (17-beta) dehydrogenase (HSD17B) enzymes catalyze the oxidoreduction of hydroxyl/keto groups of androgens and estrogens and regulate intracellular availability of steroid hormones (Mindnich et al. 2004) . To date, at least 14 different isozymes have been identified (Lukacik et al. 2006) . The type 8 17b-HSD was initially characterized as a gene whose expression was down-regulated in recessive polycystic kidney disease (PKD) in the mouse (Aziz et al. 1993) . Human and mouse HSD17B8 proteins efficiently convert estradiol (E2) into estrone (E1; Fomitcheva et al. 1998 , Ohno et al. 2007 . They also convert testosterone, 5a-dihydrotestosterone, and 5-androstene3b, 17b-diol into the corresponding 17-ketosteroid, but not with the same efficiency of E2. Despite its in vitro activity, structural studies suggested that the human protein could be involved in the metabolism of fatty acids (Pletnev & Duax 2005) .
Expression of human HSD17B8 was found to be especially abundant in the prostate, placenta, and kidney (Ohno et al. 2007) , being also detected in other tissues such as the breast, small intestine, stomach, liver, ovary, testis, and adrenals.
Expression of mouse HSD17B8 gene has been detected in several somatic tissues (Fomitcheva et al. 1998 , Woo et al. 2001 , Pelletier et al. 2005 , being particularly high in the kidney and liver.
It has been described that HSD17B8 expression is regulated by estrogens in uterus and kidney (Jelinsky et al. 2003 , Khalyfa et al. 2003 , Bourdeau et al. 2004 . Estrogens modulate transcription in their target tissues through estrogen receptor a (ERa) or ERb receptors using a number of signaling pathways. The 'classical' pathway involves direct DNA binding of the activated receptor to an estrogen response element (ERE) in the promoter region of responsive genes (Misiti et al. 2000) . The alternative, 'non-classical' pathway involves the indirect modulation of transcription by the interaction of the ER with components of other transcription complexes like FOS, SP-1, and NFkB, via protein-protein interactions (Stein & Yang 1995 , Wang et al. 1999 , DeNardo et al. 2005 , Dong et al. 2006 , Itoh et al. 2007 ). In addition, a 'non-genomic' pathway has been described in which estrogens can signal through membrane receptors involving MAP kinase signaling (Migliaccio et al. 1996) .
We have previously shown that the HSD17B8 gene is transcriptionally regulated by C/EBPb (Villar et al. 2007b ).
Moreover, two CCAAT boxes located at K5 and K46 bp of the transcription start site were required for efficient transcription of the gene in HepG2 cells. Specific binding of C/EBPb to these elements was detected and ectopic expression of C/EBPb transactivated the HSD17B8 promoter. Here, we show that HSD17B8 expression is regulated by ERa in response to E2 in HepG2 cells. The HSD17B8 expression and promoter activity were induced upon E2 stimulation in cells transfected with ERa but not in untransfected cells, which demonstrates that this induction is ERa dependent. Additional experiments showed that no ERE was necessary for E2 response. However, the mutation of either of the two CCAAT boxes impaired the E2-induced HSD17B8 promoter activity, indicating that these motifs are essential for this regulation. Immunoprecipitation and ChIP assays demonstrated that ERa regulates HSD17B8 gene in response to E2 through its interaction with C/EBPb. Taken together, our findings demonstrate that C/EBPb and ERa participate in E2-induced HSD17B8 expression.
Materials and Methods

Reagents
HepG2 and MCF-7 cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured at 37 8C in 5% CO 2 in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum, penicillin, and streptomycin. ERa (pHEO) expression vector was provided by Dr Pierre Chambon (Institut de Genitique et de Biologie Moleculaire et Cellulaire, IllkirchStrasbourg, France; Green et al. 1986 ). C/EBPb (pMSV-C/ EBPb) expression vector was a gift from Dr Steven L McKnight (UT-Southwestern Medical Center, Dallas, TX, USA; Cao et al. 1991) . Luciferase reporter plasmids were previously described (Villar et al. 2007b ). E2 and 25OH-cholesterol were supplied by Sigma-Aldrich. C/EBPb (C-19) and ERa (HC-20) antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). ICI 182 780 (Fulvestrant) was purchased from Sigma-Aldrich.
Quantitative RT-PCR
Total RNA was isolated from HepG2 cells using the RNeasy Mini Kit (Qiagen). RNA was reverse transcribed using the Superscript II kit (Invitrogen). Real-time PCR was performed with Brilliant SYBR Green Master Mix (Stratagene, La Jolla, CA, USA) and a Chromo-4 thermocycler (MJ Research, Bio-Rad). Primers used for detecting HSD17B8 mRNA were: sense strand 5 0 -ACATCAGTAGCATCG-TAGG-3 0 and antisense strand 5 0 -GGAGGACAGAGTTA-CAGC-3 0 . Primers used for detecting GAPDH were: sense strand 5 0 -GGAGTCCACTGGCGTCTTC-3 0 and antisense strand 5 0 -ATCTTGAGGCTGTTGTCATACTTC-3 0 . Results from five independent experiments, each one performed in triplicate were normalized to the level of GAPDH mRNA expressed as fold change from controls.
Transfection
Transient transfections were carried out as previously described (Villar et al. 2007b) . Briefly, 5!10 5 cells were seeded in six-well plates, in triplicate, and transfected with 2 mg HSD17B8 promoter construct plus 3 ng pRL-SV40 vector as a control for transfection efficiency. Additionally, 2 mg ERa expression vector were co-transfected when indicated. Cells were harvested 24 h later, and reporter gene activity was measured in cells extracts. Luciferase activity was determined using a Berthold Lumat LB 9501 luminometer (Berthold Technologies, Oak Ridge, TN, USA) and the dual-luciferase reporter system (Promega Corp). Data were normalized to Renilla luciferase activity and total protein concentration. pGL3 basic and pGL3 control vectors (Promega) were used as transfection controls.
Immunoprecipitation and immunoblotting
After treatments, HepG2 cells were washed with PBS 1!, trypsinized and lysed with Modified-RIPA buffer (Complete Mini-EDTA protease inhibitor tablets (Roche), 0 . 5 M TrisHCl pH 8 . 0, 10% NP-40, 1 . 5 M NaCl and H 2 O). Five hundred micrograms of protein mixtures were then precleared with 50 ml TrueBlot anti-Rabbit IP Beads (eBioscience, San Diego, CA, USA) and incubated on ice for 1 h. Supernatants were incubated with anti-ERa, anti-C/EBPb, or with a non-specific IgG control overnight at 4 8C, and were further incubated for another 4 h after the addition of 50 ml protein beads. After centrifugation, beads were washed at least five times with 500 ml lysis buffer, and eluted with 30 ml Laemmli Sample Buffer (BioRad) with 2% b-mercaptoethanol.
Methods for SDS-PAGE electrophoresis of cellular proteins, and transfer onto polyvinylidene difluoride membranes were as previously described (Alonso et al. 2003 , Villar et al. 2007a . Membranes were incubated with anti-ERa or anti-C/EBPb; washed with Tween 20 in PBS; incubated with peroxidase-conjugated secondary antibody; and the signal was then detected with a chemiluminescence-based system (Pierce, Rockford, IL, USA).
Chromatin immunoprecipitation (ChIP) assay
ChIPs were performed using the ChIP Kit and Shearing Kit (Active Motif, Carlsbad, CA, USA). HepG2 cells were fixed with 37% formaldehyde and lysed according to the manufacturer's instructions. Chromatin was sheared by sonication on ice, and agarose gel electrophoresis was used to select chromatin fragments with an average size of %500 bp. Primers 5 0 -CCTAAGCAGCAGTGTCGG-3 0 (upper strand) and 5 0 -TGTGGGTGGGTGGGAATC-3 0 (lower strand) were used for PCR amplification of input DNA and DNA precipitated with anti-C/EBPb, anti-ERa, or with a nonspecific control IgG. Primers were designed to amplify a 167-bp fragment of the HSD17B8 proximal promoter (positions K142 to C25) that encompasses the CCAAT boxes required for promoter activity.
Statistical analysis
Data were analyzed using one-factor ANOVAs. Following significance in the ANOVAs, data were subjected to analysis with Tanhane posttests in which the value necessary for significance (P!0 . 05) is lowered by dividing the number of comparisons that are made. Analysis was done using SPSS 12.0 for Windows (Chicago, IL, USA). Results are expressed as meanGS.E.M.
Results
E2 increases the expression of HSD17B8 in an ERa-dependent manner
Microarray studies in uterus and kidney have shown that HSD17B8 could be regulated by estrogens in those tissues (Jelinsky et al. 2003 , Khalyfa et al. 2003 . To confirm whether or not this gene is regulated by estrogens, we treated the breast cancer cell line MCF-7 with E2 10 K8 M for 24 h. Real time RT-PCR showed that E2 treatment induced HSD17B8 expression by about 2 . 5-fold (Fig. 1A) . Importantly, the anti-ER ICI 182 780 suppressed this induction, which suggested that this process is ER-dependent. To confirm this, HepG2 cells, a hepatocarcinoma cell line that does not express ERa, were treated with E2. As expected, E2 treatment does not increase HSD17B8 expression (Fig. 1B) . However, when HepG2 cells were transfected with an ERa expression vector, E2 induced HSD17B8 expression by about 2 . 5-fold. More importantly, the anti-ER ICI 182 780 suppressed this induction which confirms that E2-induced HSD17B8 expression is dependent on ERa. Taken together, these results clearly demonstrate that HSD17B8 expression is induced by E2 by a mechanism mediated by ERa.
E2 increases the expression of HSD17B8 in an EREindependent mechanism
To further investigate the E2 activation of HSD17B8 transcription, we tested whether the promoter region of the HSD17B8 gene responded to E2. HepG2 cells were transfected with pJV260, a construct that contained the most active part of the HSD17B8 promoter, and treated with E2 10 K8 M for 24 h. As shown in Fig. 2 , E2 treatment increased the HSD17B8 promoter activity more than 2-fold. Once again, this induction was only observed in the cells expressing ERa, which confirmed that E2-induced HSD17B8 expression is mediated by ERa. pGL3-promoter that was used as negative control and pERE, a plasmid carrying three copies of the vitellogenin ERE cloned upstream of the luciferase gene into pGL3-promoter, was used as positive control. Taken together, these data confirm that HSD17B8 expression is regulated by E2 and this is mediated by ERa.
Computational analysis on the human HSD17B8 promoter revealed the presence of a putative ERE half-site located at K82 (Villar et al. 2007b) . ERa is able to activate transcription through ERE half-sites either binding directly to DNA (Kato et al. 1992 , Ediger et al. 2002 or binding to other transcription factors previously bound to this element (Stossi et al. 2006 ). To evaluate whether or not this ERE half-site participates in E2-induced HSD17B8 expression, HepG2 cells were co-transfected with ERa and pJV260 pJV150, or pJV75. pJV260 and pJV150 constructs contained the ERE half-site. However, pJV75 is a deletion construct lacking this element. As shown in Fig. 2 , treatment with E2 induced the promoter activity of all of them by more than 2-fold, which demonstrates that this element is not implicated in the regulation of HSD17B8 expression and suggests that HSD17B8 gene is transcriptionally regulated by E2 in an ERE-independent mechanism. E2 action on HSD17B8 is through the CCAAT boxes presented at the promoter of the gene Previous studies demonstrated that two CCAAT boxes located at K5 and K46 are essential for HSD17B8 promoter activity (Villar et al. 2007b) . Furthermore, C/EBPb bound to these boxes in vitro and transactivated the HSD17B8 K8 M E2 and 10 K7 M ICI alone or in combination for 24 h, in the presence or absence of ERa. Afterwards, RNA was extracted and HSD17B8 expression measured by qPCR. GAPDH was used as loading control. Columns, mean of five independent experiments promoter activity. After showing that E2 induces the transcriptional activity of the minimal promoter, it became important to explore whether or not these CCAAT boxes participate in E2-induced HSD17B8 promoter activity. Therefore, HepG2 cells were transfected with pJV260 or with constructs in which these CCAAT boxes are mutated. E2 treatment increased the promoter activity of the wild-type pJV260 by about 2 . 5-fold. However, mutation of either of the two CCAAT boxes prevented the E2-induced HSD17B8 promoter activity (Fig. 3 ). These results demonstrate that CCAAT boxes located at K5 and K46 relative to the start site are necessary for E2-induced HSD17B8 transcription.
Estrogens do not regulate C/EBPb expression in HepG2 cells
Estrogens are known to regulate expression of some transcription factors like C-MYC (Dubik et al. 1987) , FOS, Sp1, and NF-YA (Dong et al. 2007) . Recently, it has been described that dehydroepiandrosterone modulates the transcription of HSD11B2 by increasing C/EBPb expression (Balazs et al. 2007 ). Since C/EBPb transactivates HSD17B8, upregulation of C/EBPb by E2 would explain the induction of HSD17B8 expression by E2. To check if E2 increases C/ EBPb expression, MCF-7 and HepG2 cells expressing ERa were treated with E2 10 K8 M. Real time RT-PCR showed that E2 does not induce HSD17B8 expression in either of the cell lines (Fig. 4) , which clearly indicates that E2-induced HSD17B8 expression is not mediated by the upregulation of C/EBPb.
C/EBPb and ERa interact in HepG2 cells expressing ERa
A direct interaction between ERa and C/EBPb bound to DNA has been described in MCF-7 cells (Dong et al. 2006 ). Since C/EBPb transactivates HSD17B8 (Villar et al. 2007b) and E2-induced HSD17B8 expression is ERE-independent, we then decided to test whether or not ERa interacts with C/EBPb to promote HSD17B8 expression in response to E2. Therefore, HepG2 cells expressing ERa were treated with E2 and co-immunoprecipitation assays with C/EBPb (Fig. 5A) or ERa (Fig. 5B ) specific antibodies were performed. Immunoprecipitated complexes were detected with either ERa (Fig. 5A ) or C/EBPb (Fig. 5B) . IgG was included as negative control. In the absence of E2, ERa showed minimal interaction with C/EBPb (Fig. 5A and B, middle panels). However, upon E2 treatment there was an increase in the amount of the complex formed between ERa and C/EBPb (Fig. 5A and B, bottom panels) . No interaction was observed in cells not expressing ERa (Fig. 5A and B, top panels) . Taken together these results indicate that E2 promotes the formation of a complex between ERa and C/EBPb.
Recruitment of ERa to HSD17B8 promoter in response to E2
After showing that E2 induces the formation of the complex ERa-C/EBPb, we next investigated the recruitment of ERa Figure 3 CCAAT boxes are essential for the E2-induced HSD17B8 expression. CCAAT boxes located at K5 (pMC1) and K46 (pMC2) were mutated. HepG2 cells were co-transfected with the different mutants and the ERa expression vector, and treated with 10 K8 M E2. Promoter activity was determined as previously described and expressed as -fold over control (cells treated with vehicle). Columns, mean of five independent experiments each done in triplicate; bars, S.E.M., *P!0 . 05, in all cases.
Figure 2 E2 increases the HSD17B8 promoter activity in an EREindependent manner. HepG2 cells were transfected with various human HSD17B8 promoter deletion constructs (schematic on the left) in the presence or absence of E2 10 K8 M and ERa. Promoter activity (right) was determined as described in Materials and Methods and expressed as -fold over control (cells treated with vehicle). Columns, mean of five independent experiments each done in triplicate; bars, S.E.M., *P!0 . 05, in all cases.
M ROTINEN and others . ERa interacts with C/EBPb to promote E2-induced HSD17B8 expression and C/EBPb to the HSD17B8 promoter in response to E2. Therefore, ChIP assays were performed in HepG2 cells expressing ERa treated with 10 K8 M E2 or vehicle. HepG2 cells not expressing ERa exposed to vehicle were used as a control. Chromatin was immunoprecipitated with ERa, C/EBPb, or IgG specific antibodies. For PCR analysis a set of primers that amplified a fragment that encompassed the CCAAT boxes located within the proximal promoter of HSD17B8 were used (Fig. 6A) . As expected, no ERa recruitment was observed in cells not expressing ERa (Fig. 6B, top panel) . Interestingly, in the absence of hormone, ERa was slightly recruited to the HSD17B8 promoter (6B, middle panel). However, after E2 treatment, the recruitment of ERa to the HSD17B8 promoter was highly induced (6B, lower panel). On the other side, recruitment of C/EBPb to the HSD17B8 promoter was not affected by E2 treatment nor ERa expression, which suggests that C/EBPb is not affected by E2 treatment. Based on these findings, we conclude that in response to E2, ERa binds to C/EBPb already bound to HSD17B8 5 0 untranslated region promoting its expression.
Discussion
HSD17B8 protein efficiently converts E2 into E1 in vitro, which suggests that it might be involved in the metabolism of estrogens. Here, we show that HSD17B8 is regulated by estrogens (Figs 1 and 2) , and that this regulation is ERamediated. Results from MCF-7 cells (Fig. 1A) , a breast cancer K8 M E2 for 24 h in the presence or absence of ERa. Then, RNA was extracted and C/EBPb expression was measured by qPCR. GAPDH was used as loading control. Columns, mean of five independent experiments each done in triplicate; bars, S.E.M., *P!0 . 05, in all cases. K8 M E2 or vehicle for 24 h in the presence or absence of ERa. After treatments, cells were harvested and protein complexes immunoprecipitated (IP) using specific antibodies against C/EBPb, ERa, or control IgG. Western blots (WB) with (A) C/EBPb or (B) ERa specific antibodies were performed as described in Materials and Methods. cell line ERa positive, and from HepG2 cells (Fig. 1B) , a hepatocarcinoma cell line with no ERa expression, revealed that in the presence of ERa E2-induced HSD17B8 expression by about 2 . 5-fold. This induction was blocked by the addition of the anti-estrogens ICI 182 780, and no induction was observed in the absence of ERa in HepG2 cells, which clearly demonstrates that E2-induced HSD17B8 expression is through ERa. Our results confirm previous results that showed that the HSD17B8 gene is regulated by estrogens in uterus and kidney (Jelinsky et al. 2003 , Khalyfa et al. 2003 , Bourdeau et al. 2004 . The biological effects of estrogens are mediated by ERa and ERb, which are members of the superfamily of nuclear receptors (Bjornstrom & Sjoberg 2005) . The classical mechanism of ER action involves estrogens binding to receptors in the nucleus, after which the receptors dimerize and bind to specific response elements (ERE) in the promoter of target genes. Although, Bourdeau et al. identified a putative ERE about 3 kb upstream of the transcription start site of the human HSD17B8, we demonstrate that transcriptional regulation of HSD17B8 by ERa does not require direct binding of the agonist-activated ERa to this element (Fig. 2) . The human HSD17B8 proximal promoter contains an ERE half-site located at K82. It has been described that ERE half-sites bind ERa but not ERb (Vanacker et al. 1999) . Our results clearly show that not the ERE half-site but CCAAT boxes present in the human HSD17B8 proximal promoter are required for the induction of HSD17B8 expression by E2 (Fig. 3) .
In addition to the classical mechanism, two other different mechanisms called non-genomic and non-classical have been described for ER action. The non-classical mechanism, often referred as transcriptional crosstalk, involves tethering of the receptor with other transcription factor complexes that contact the DNA. In previous work, we demonstrated that CCAAT boxes located at K5 and K46 contribute dramatically to the basal promoter activity of HSD17B8. We also detected specific binding of C/EBPb to those motives, and we showed that ectopic expression of C/EBPb transactivated the HSD17B8 promoter. Here, we describe that C/EBPb and ERa crosstalk to promote HSD17B8 transcription in response to E2 (Figs 5 and 6) . Interestingly, previous studies have shown C/EBPb and ERa transcriptional crosstalk, to repress the human IL6 promoter in human osteoblast cell lines (Stein & Yang 1995) and to activate the human prolactin receptor gene in human breast cancer MCF-7 cells (Dong et al. 2006) . In the latter, E2 induced the formation of a complex between C/EBPb, Sp1, and ERa. In the present study, using co-IP, we provide strong evidence of an interaction between ERa and C/EBPb in response to E2 in human hepatoma HepG2 cells (Fig. 5) . Our results also show that E2 induces recruitment of ERa but not C/EBPb to the HSD17B8 promoter (Fig. 6 ). This suggests that E2-activated ERa tethers to C/EBPb already bound to the HSD17B8 promoter, thus, enhancing its expression.
C/EBPb belongs to a family of transcription factors that contain a highly conserved, basic leucine zipper domain at the C-terminus that is involved in dimerization and DNA binding (Ramji & Foka 2002) . C/EBPb is a critical regulator of proliferation and/or differentiation in multiple tissues, including the liver, adipose tissue, immune system, and mammary gland (Wedel & Ziegler-Heitbrock 1995 , Greenbaum et al. 1998 , Seagroves et al. 1998 , Tang et al. 2003 . Importantly, C/EBPb is essential for female reproduction because of a critical role in ovarian follicle development (Sterneck et al. 1997) . C/EBPb is known to be a critical mediator of steroid hormone responsiveness in the uterus (Mantena et al. 2006) , where it mediates E2-induced epithelium proliferation and, additionally, is rapidly induced by E2. In the present study, we clearly show that the induction of HSD17B8 expression by E2 in HepG2 cells is not due to an increase in C/EBPb expression after E2 treatment (Fig. 4) .
C/EBPbs transcription factors have been involved in the regulation of HSD11B1 and 11b-HSD2, enzymes involved in glucocorticoid metabolism (Williams et al. 2000 , Gout et al. 2006 . Impaired intracellular metabolism of steroids has been suggested to contribute to the development of various pathologic conditions including PKD. Interestingly, HSD17B8 and HSD11B1 expression are downregulated in PKD (Aziz et al. 1994) , which suggests that C/EBPbs transcription factor might play an important role in PKD. A significant decrease in HSD17B8 expression has also been described in tumor tissue of oral cavity patients without lymph node metastasis compared with its surrounding healthy tissue (Reinders et al. 2007 ). Whether or not ERa and C/EBPb play a role in this downregulation remains to be investigated.
In conclusion, the fact that HSD17B8 converts E2 into E1 suggests that HSD17B8 plays an important role in the control of the intracellular levels of active estrogens. Here, we show that estrogens regulate the expression of HSD17B8, a gene implicated in their own regulation. We also provide strong evidence of C/EBPb role in E2/ERa mediated HSD17B8 expression. However, the molecular mechanisms underlying the effects of estrogens are likely to be specific for the cell type, and thus, the gene responses are likely to be diverse. Therefore, additional experiments are required to demonstrate if HSD17B8 is regulated by E2 in tissues where estrogens play an important role in the initiation and progression of cancer.
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